AtriCure (NASDAQ:ATRC) Given New $70.00 Price Target at Needham & Company LLC

AtriCure (NASDAQ:ATRC) had its price objective upped by analysts at Needham & Company LLC from $64.00 to $70.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical device company’s stock. Needham & Company LLC‘s target price indicates a potential upside of 15.87% from the company’s previous close.

Several other equities analysts have also recently weighed in on the stock. Piper Sandler lifted their price objective on shares of AtriCure from $50.00 to $60.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. Citizens Jmp increased their target price on AtriCure from $52.00 to $68.00 and gave the company a “market outperform” rating in a report on Wednesday, October 21st. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Weiss Ratings raised AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Stifel Nicolaus set a $65.00 price target on AtriCure in a report on Thursday, September 17th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $57.00.

AtriCure Stock Performance

AtriCure stock opened at $60.41 on Wednesday. The firm’s 50 day simple moving average is $56.03 and its 200-day simple moving average is $38.40. The company has a market cap of $3.07 billion, a P/E ratio of 260.35 and a beta of 1.23. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure has a fifty-two week low of $25.36 and a fifty-two week high of $63.00.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.23. The business had revenue of $154.45 million for the quarter, compared to analyst estimates of $151.05 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. As a group, equities research analysts predict that AtriCure will post 0.29 EPS for the current year.

Insider Buying and Selling at AtriCure

In other news, insider Karl Dahlquist sold 9,370 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total transaction of $458,099.30. Following the transaction, the insider directly owned 87,319 shares in the company, valued at $4,269,025.91. The trade was a 9.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Salvatore Privitera sold 4,519 shares of the company’s stock in a transaction on Wednesday, September 23rd. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00. Following the completion of the transaction, the insider directly owned 142,745 shares in the company, valued at $8,564,700. This trade represents a 3.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 30,622 shares of company stock valued at $1,626,003 in the last quarter. Company insiders own 4.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Harbor Investment Advisory LLC bought a new position in shares of AtriCure during the 2nd quarter valued at $40,000. Allworth Financial LP bought a new stake in AtriCure in the second quarter worth $43,000. Integrated Wealth Concepts LLC acquired a new position in AtriCure during the second quarter worth $46,000. Sterling Capital Management LLC increased its position in AtriCure by 841.1% during the third quarter. Sterling Capital Management LLC now owns 1,647 shares of the medical device company’s stock worth $93,000 after buying an additional 1,472 shares during the last quarter. Finally, Fifth Third Bancorp bought a new position in AtriCure during the first quarter valued at about $51,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

AtriCure News Summary

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported third-quarter EPS of $0.17 and revenue of $154.45 million, beating analyst estimates of $151.05 million in revenue. The better-than-expected results prompted analysts to increase their forecasts. AtriCure beats Q3 estimates
• Positive Sentiment: BTIG raised its price target to $70, while broader analyst coverage also reported upward forecast revisions after the quarterly results. Such revisions signal improved expectations for the company. BTIG raises AtriCure price target
• Positive Sentiment: The company expects 2026 revenue of $606 million to $610 million and adjusted EBITDA of $91 million to $94 million, providing investors with its latest financial outlook. AtriCure 2026 outlook and enrollment update
• Neutral Sentiment: AtriCure is targeting completion of BoxX-NoAF enrollment by year-end. This is a clinical-program milestone, though the article listing provides no results or details on potential timing or impact. BoxX-NoAF enrollment update

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.